Bahija Jallal, Ph.D.

Bahija Jallal, Ph.D.

Chief Executive OfficeratImmunocore Holdings· In proxies 2017–2025

Pay in FY2025-15% from the year before · Immunocore Holdings stock +17.7% the same year

Bahija Jallal, Ph.D. was paid $10.9M in FY2025 (Dec), down 15%. Immunocore Holdings stock rose 17.7% that year.

Pay$100 in the stock at the end of FY21 → $101
Pay is from the Summary Compensation Table of each Immunocore Holdings proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Immunocore HoldingsPublic company · 4 yr
    • Chief Executive Officer2022 – Present · 4 yrStock in role -5%
  2. Elevance HealthPublic company · 9 yr
    • Director2017 – Present · 9 yrNo stock prices for these years
  3. Immunocore Holdings plc DirectorPublic company · 7 yr
    • Director2019 – Present · 7 yrNo stock prices for these years
  4. Anthem, Inc.Public company · 8 yr
    • Director2018 – Present · 8 yrNo stock prices for these years
  5. DirectorPublic company
    • Director? – PresentNo stock prices for these years
  6. Immunocore Holdings plcPublic company
    • Director? – PresentNo stock prices for these years
  7. ArriVent BioPharma, Inc.Public company · 2 yr
    • Director2022 – 2024 · 2 yrNo stock prices for these years
  8. Arrivent Biopharma, Inc.Public company · 2 yr
    • Director2022 – 2024 · 2 yrNo stock prices for these years
  9. Guardant Health, Inc.Public company · 3 yr
    • Director2019 – 2022 · 3 yrNo stock prices for these years
  10. Guardant Health, Inc.Public company · 3 yr
    • Director2019 – 2022 · 3 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Elevance HealthDirector · 7 yr on the boardIndependentCompensation and Talent, Governance (Chair)—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?